Rhythm Biosciences Ltd. (RHY) Price & Analysis

Compare

13 Followers

RHY Stock Chart & Stats

AU$0.14

<AU$0.01(1.16%)

At close: Jan 09 4:00 PM EST

AU$0.14

<AU$0.01(1.16%)

Day’s Range― - ―

52-Week RangeAU$0.05 - AU$0.28

Previous CloseN/A

Volume786.78K

Average Volume (3M)462.98K

Market Cap

AU$71.07M

Enterprise ValueAU$69.13M

Total Cash (Recent Filing)AU$1.73M

Total Debt (Recent Filing)AU$262.44K

Price to Earnings (P/E)―

Beta0.93

Next Earnings

Aug 27, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)>-0.01

Shares Outstanding338,407,140

10 Day Avg. Volume510,821

30 Day Avg. Volume462,976

Financial Highlights & Ratios

PEG Ratio0.07

Price to Book (P/B)22.03

Price to Sales (P/S)4.56

P/FCF Ratio-4.94

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clear Product Focus: ColostatA single, well‑defined product program (Colostat) targeting colorectal cancer screening creates a focused commercial and regulatory strategy. Over months this supports targeted reimbursement efforts, clearer clinical evidence generation, and scalable deployment into population screening and clinical pathways, improving go‑to‑market clarity and resource allocation.

High Gross Profit MarginA high gross profit margin indicates underlying unit economics that can absorb sales and marketing investment when volume grows. Structurally this supports long‑term margin expansion as fixed costs are leveraged, enabling the company to move toward operating profitability if commercial uptake and scale progress as planned.

Improving Free Cash Flow TrendsImproving free cash flow trends, with FCF roughly covering net income, signal better cash conversion and operational discipline. Over a multi‑month horizon this reduces near‑term external financing needs, supports continued clinical/commercial investment, and improves runway for scaling the business if the trend continues.

Bears Say

Sharp Revenue DeclineA 42.87% revenue drop is a durable red flag for commercial traction and market adoption. Sustained top‑line declines strain fixed cost absorption, undermine return on clinical and commercial investments, and increase reliance on external capital or cost cuts to maintain development and regulatory programs over the coming months.

Negative Operating Cash FlowPersistent negative operating cash flow indicates the core business is not yet self‑funding. Over 2–6 months this requires continued financing or drawdowns, which can dilute shareholders or constrain commercial expansion; it also limits flexibility to invest in evidence generation and market access initiatives critical for diagnostics adoption.

High Leverage And Negative ROEA debt/equity ratio of 1.68 combined with negative ROE raises solvency and cost‑of‑capital concerns. Structurally, elevated leverage increases interest burden and refinancing risk, limiting the firm's ability to fund clinical rollouts or absorb setbacks without dilutive capital, which can hinder long‑term commercialization plans.

Rhythm Biosciences Ltd. News

Rhythm Biosciences Scales ColoSTAT Rollout via 4Cyte Pathology Network

Rhythm Biosciences Ltd. ( ($AU:RHY) ) has provided an announcement. Rhythm Biosciences has accelerated the commercial rollout of...

22h ago

RHY

Rhythm Biosciences Issues Cautionary Business Update

Rhythm Biosciences Ltd. ( ($AU:RHY) ) has provided an announcement. Rhythm Biosciences Limited has issued a business update...

22h ago

RHY

Rhythm Biosciences Seeks ASX Quotation for Additional Ordinary Shares

Rhythm Biosciences Ltd. ( ($AU:RHY) ) has provided an update. Rhythm Biosciences Ltd has applied for quotation on...

6d ago

RHY

Rhythm Biosciences launches commercial operations with first ColoSTAT test sale

An update from Rhythm Biosciences Ltd. ( ($AU:RHY) ) is now available. Rhythm Biosciences has completed the first...

8d ago

RHY

Rhythm Biosciences Wins NATA Accreditation for ColoSTAT Cancer Test

Rhythm Biosciences Ltd. ( ($AU:RHY) ) has shared an announcement. Rhythm Biosciences has secured National Association of Testing...

10d ago

RHY

Rhythm Biosciences Seeks ASX Quotation for New Ordinary Shares

Rhythm Biosciences Ltd. ( ($AU:RHY) ) has shared an announcement. Rhythm Biosciences has applied to the ASX for...

13d ago

RHY

Rhythm Biosciences inks first Southeast Asia geneType distribution deal

Rhythm Biosciences Ltd. ( ($AU:RHY) ) just unveiled an update. Rhythm Biosciences has signed a 12‑month supply and...

15d ago

RHY

Rhythm Biosciences Issues New Shares and Lodges Cleansing Notice

Rhythm Biosciences Ltd. ( ($AU:RHY) ) just unveiled an announcement. Rhythm Biosciences has issued 413,793 new ordinary shares...

20d ago

RHY

Rhythm Biosciences Seeks ASX Quotation for 413,793 New Shares

An announcement from Rhythm Biosciences Ltd. ( ($AU:RHY) ) is now available. Rhythm Biosciences Ltd. has applied for...

20d ago

RHY

Rhythm Biosciences Seeks ASX Quotation for Additional Ordinary Shares

Rhythm Biosciences Ltd. ( ($AU:RHY) ) has issued an update. Rhythm Biosciences Ltd. has applied to the ASX...

20d ago

RHY

RHY FAQ

What was Rhythm Biosciences Ltd.’s price range in the past 12 months?

Rhythm Biosciences Ltd. lowest share price was AU$0.05 and its highest was AU$0.28 in the past 12 months.

What is Rhythm Biosciences Ltd.’s market cap?

Rhythm Biosciences Ltd.’s market cap is AU$71.07M.

When is Rhythm Biosciences Ltd.’s upcoming earnings report date?

Rhythm Biosciences Ltd.’s upcoming earnings report date is Aug 27, 2026 which is in 162 days.

How were Rhythm Biosciences Ltd.’s earnings last quarter?

Rhythm Biosciences Ltd. released its earnings results on Feb 18, 2026. The company reported -AU$0.007 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.007.

Is Rhythm Biosciences Ltd. overvalued?

According to Wall Street analysts Rhythm Biosciences Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Rhythm Biosciences Ltd. pay dividends?

Rhythm Biosciences Ltd. does not currently pay dividends.

What is Rhythm Biosciences Ltd.’s EPS estimate?

Rhythm Biosciences Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Rhythm Biosciences Ltd. have?

Rhythm Biosciences Ltd. has 338,407,140 shares outstanding.

What happened to Rhythm Biosciences Ltd.’s price movement after its last earnings report?

Rhythm Biosciences Ltd. reported an EPS of -AU$0.007 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 2.381%.

Which hedge fund is a major shareholder of Rhythm Biosciences Ltd.?

Currently, no hedge funds are holding shares in AU:RHY

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Rhythm Biosciences Ltd. Stock Smart Score

Outperform

Fundamentals

Return on Equity

-476.27%

Trailing 12-Months

Asset Growth

-47.76%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Rhythm Biosciences Ltd.

Rhythm Biosciences Limited, a transformative predictive cancer diagnostics technology company in Australia and internationally. The company engages in developing and commercializing medical diagnostics technology. It develops ColoSTAT, a blood test for the early detection of colorectal cancer. The company was incorporated in 2017 and is headquartered in Parkville, Australia.